Issue 5/2012

  • It's finally spring for EU biotechs

    In this issue:

    • Austrian efforts to implement a total national ban on GMOs
    • Finland's UPM invests €150m in biodiesel refinery
    • AstraZeneca to take over US gout drug specialist Ardea
    • SPECIAL: Contract Research – Opportunities for outsourcing
    • Cancer start-up Vivia Biotech secures Series B financing 
    • Gedeon Richter opens huge biologics manufacturing plant
    • Databases link cancer cell genomics to drug efficacy

Volume 2016

Volume 2015

Volume 2014

Volume 2013

Volume 2012

© 2007-2016 BIOCOM

http://www.european-biotechnology-news.com/magazine/ebsin/2012/5/pos/1.html?cHash=2aa63e7a3c47f54d547eeaaa494e591b&sort=asc

Kurszettel

Alle Kurse

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • NOVACYT (F)1.63 EUR17.27%
  • PLETHORA (UK)3.38 GBP12.67%

FLOP

  • BAYER (D)84.42 EUR-5.72%
  • ALMIRALL (E)13.37 EUR-5.51%
  • MOLOGEN (D)3.20 EUR-5.04%

TOP

  • GALAPAGOS (B)51.25 EUR28.6%
  • NICOX (F)10.90 EUR26.2%
  • GENMAB (DK)1205.00 DKK24.2%

FLOP

  • BIONOR PHARMA (N)0.68 NOK-26.9%
  • MOBERG PHARMA (S)38.70 SEK-26.3%
  • BIOCARTIS GROUP NV (B)8.00 EUR-24.2%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)28.90 SEK1906.9%
  • NICOX (F)10.90 EUR489.2%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)5.90 SEK-86.6%
  • BB BIOTECH (D)43.88 EUR-84.9%
  • EVOCUTIS (UK)0.05 GBP-79.2%

No liability assumed, Date: 23.05.2016